That's actually pretty big news
"The patent, according to Dr. Jonathan Faro, chief medical officer for NanoLogix, has wide-ranging implications, from “those who would like to determine if a convalescent serum has effective antibodies capable of neutralizing the virus” to “those who would like to know if an individual is contagious, or if they have gotten over the virus and can now go back to work.”
“This has implications for those who get the vaccine, but they would like to know if they seroconverted and may safely return to work,” Faro wrote."
"The patent also impacts people ready to get a vaccine, but want to make sure they are not an asymptomatic carrier and don’t need it, and medications and treatment strategies.
“In effect, none of these may continue without possibly infringing on our patent,”
News 
Market Data 
Discover 
